These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26896751)

  • 1. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
    Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
    Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
    Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
    J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Vigarios E; Lamant L; Delord JP; Fricain JC; Chevreau C; Barrés B; Gomez-Roca C; Boulanger M; Sibaud V
    Br J Dermatol; 2015 Jun; 172(6):1680-1682. PubMed ID: 25495246
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
    Viros A; Hayward R; Martin M; Yashar S; Yu CC; Sanchez-Laorden B; Zambon A; Niculescu-Duvaz D; Springer C; Lo RS; Marais R
    J Invest Dermatol; 2013 Jan; 133(1):274-6. PubMed ID: 22895366
    [No Abstract]   [Full Text] [Related]  

  • 7. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
    Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
    J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
    Anforth R; Tembe V; Blumetti T; Fernandez-Peñas P
    Pigment Cell Melanoma Res; 2012 Sep; 25(5):569-72. PubMed ID: 22726224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.
    Adelmann CH; Ching G; Du L; Saporito RC; Bansal V; Pence LJ; Liang R; Lee W; Tsai KY
    Oncotarget; 2016 May; 7(21):30453-60. PubMed ID: 27028853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
    Erfan G; Puig S; Carrera C; Arance A; Gaba L; Victoria I; Garcia-Herrera A; Alos L; Malvehy J
    Acta Derm Venereol; 2017 Feb; 97(2):258-260. PubMed ID: 27353949
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.
    Satzger I; Degen A; Asper H; Kapp A; Hauschild A; Gutzmer R
    J Clin Oncol; 2013 May; 31(13):e220-2. PubMed ID: 23530102
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
    Cassius C; Pages C; Roux J; Lhote R; Lavocat R; Réa D; Bagot M; Mourah S; Battistella M; Lebbé C; Dumaz N
    J Invest Dermatol; 2016 Jun; 136(6):1302-1305. PubMed ID: 26854489
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous effects of BRAF inhibitor therapy: a case series.
    Mattei PL; Alora-Palli MB; Kraft S; Lawrence DP; Flaherty KT; Kimball AB
    Ann Oncol; 2013 Feb; 24(2):530-537. PubMed ID: 23035153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
    Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
    Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BRAF: the pathologist's favorite oncogene].
    Sabourin JC
    Ann Pathol; 2013 Dec; 33(6):373-4. PubMed ID: 24331718
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
    Anforth R; Blumetti TC; Clements A; Kefford R; Long GV; Fernandez-Peñas P
    Br J Dermatol; 2013 Dec; 169(6):1310-3. PubMed ID: 23870055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
    Sinha R; Larkin J; Fearfield L
    Br J Dermatol; 2015 Apr; 172(4):1135-6. PubMed ID: 25234953
    [No Abstract]   [Full Text] [Related]  

  • 20. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
    Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
    J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.